Ipamorelin and CJC-1295 without DAC (also referred to as CJC No DAC or Modified GRF 1-29) are two synthetic peptides that have attracted sustained interest in the field of growth hormone research. Both compounds act on distinct but complementary points within the growth hormone secretion pathway, and it is precisely this mechanistic synergy that has led researchers to examine them in combination. This article is intended for scientific researchers seeking a structured overview of these compounds and the rationale behind their combined study.
Understanding the Individual Compounds
Ipamorelin
Ipamorelin is a pentapeptide and a selective growth hormone secretagogue receptor (GHSR) agonist. It belongs to the ghrelin mimetic class and stimulates pituitary release of growth hormone through the ghrelin receptor pathway. What distinguishes ipamorelin within this class is its reported selectivity — preclinical studies have noted that it does not appear to significantly stimulate the release of ACTH or cortisol at research-relevant doses, which has made it a compound of considerable interest in controlled laboratory settings. Researchers exploring growth hormone dynamics can find ipamorelin listed within the Growth Hormone compounds category.
CJC-1295 Without DAC (Modified GRF 1-29)
CJC-1295 without DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH). Unlike the DAC-containing version, which incorporates a drug affinity complex to extend plasma half-life significantly, the no-DAC variant has a shorter active window — estimated at approximately 30 minutes — that more closely mirrors endogenous GHRH pulsatility. This characteristic has made it a preferred tool in research protocols that seek to replicate physiological patterns of growth hormone release rather than sustained pharmacological elevation.
The Rationale for Studying Them Together
The combination of ipamorelin and CJC No DAC has become a focal point in growth hormone research because the two compounds operate on separate but synergistic receptor systems. CJC No DAC acts on GHRH receptors to prime somatotroph cells within the anterior pituitary, while ipamorelin acts via the GHSR pathway to amplify the resultant GH pulse. When used in parallel, preclinical data has suggested that this dual stimulation produces a greater and more defined GH pulse compared to either compound administered independently.
This mechanistic complementarity aligns with findings published in the peer-reviewed literature. Bowers et al. (1996) documented the additive effects observed when GHRH and GHSR agonists were co-administered in animal models, providing an early mechanistic basis for the dual-pathway approach that researchers continue to explore today.
Further foundational work by Raun et al. (1998) characterised the high selectivity and potency of ipamorelin relative to earlier secretagogues, helping to establish its utility as a research tool within this combined framework. Their data supported the understanding that ipamorelin’s specificity makes it particularly suited to controlled experimental protocols.
Key Considerations for Researchers
Researchers designing protocols involving these compounds should be aware of several factors that can influence experimental outcomes:
- The short half-life of CJC No DAC requires careful timing in experimental design to ensure synchronisation with ipamorelin administration.
- Both compounds are synthetic peptides requiring appropriate storage conditions, typically lyophilised and reconstituted under sterile laboratory conditions.
- Given that the combination targets the GH axis, researchers should consider appropriate assay selection — including IGF-1 measurement — when designing outcome metrics.
- Baseline hormonal profiling in animal models is advisable to reduce experimental variability.
Researchers interested in broader peptide science are encouraged to consult the Peptide Encyclopedia for detailed mechanistic profiles on these and related compounds.
Key Takeaways
- Ipamorelin is a selective GHSR agonist; CJC No DAC is a short-acting GHRH analogue.
- Their combined study is supported by the distinct but complementary receptor pathways they engage.
- Preclinical data suggests the combination produces amplified GH pulses relative to either compound alone.
- CJC No DAC’s pulsatile activity profile differentiates it meaningfully from the DAC-containing variant.
- Both compounds are available as research-grade peptides for qualified laboratory investigators.
Frequently Asked Questions
What does “No DAC” mean in CJC-1295 No DAC?
DAC stands for Drug Affinity Complex, a lysine-maleimide modification that binds the peptide to albumin in plasma, extending its half-life to several days. Removing the DAC results in a compound with a much shorter active window, making it more representative of natural GHRH pulsatility in research contexts.
Are these compounds suitable for human use?
No. Ipamorelin and CJC No DAC are research compounds available exclusively for laboratory investigation. They are not approved for human administration and should not be used outside of a controlled research setting.
Where can researchers access these compounds in the UK?
UK-based researchers can browse available research-grade peptides, including growth hormone compounds, through the Growth Hormone section or view the full catalogue at RnD Peptides.
Why is the combination studied rather than individual compounds?
The combination is studied because the two compounds engage distinct but synergistic mechanisms. GHRH receptor activation by CJC No DAC and GHSR activation by ipamorelin together appear to produce a more pronounced GH secretory response than either agent alone, according to available preclinical data.
This content is intended for qualified scientific researchers only. All compounds are for laboratory research use only. Not for human consumption.
